Medigene/Nordic enter agreement for Veregen in Eastern European and CIS countries

Medigene and Nordic Pharma have entered into an exclusive agreement for the supply and marketing of Veregen (sinecatechins 15 % ointment; formerly known as Polyphenon E) for the treatment of genital warts in the Czech Republic, Slovakia, Poland, Hungary, the Baltic countries, Georgia and the CIS. Medigene will benefit from milestone payments and double-digit royalties on sales of Veregen in these countries, as well as certain payments related to the manufacture and supply of the finished product.

Nordic is planning to launch Veregen in the Czech Republic, Slovakia, Poland and Hungary during 2013. MAAs for the other countries are in preparation.

After conclusion of this agreement, marketing partnerships for Veregen now exist for all 17 countries included in the second wave of the European approval procedure, as well as for numerous other markets.

Medigene/Nordic enter agreement for Veregen in Eastern European and CIS countries

Medigene and Nordic Pharma have entered into an exclusive agreement for the supply and marketing of Veregen (sinecatechins 15 % ointment; formerly known as Polyphenon E) for the treatment of genital warts in the Czech Republic, Slovakia, Poland, Hungary, the Baltic countries, Georgia and the CIS. Medigene will benefit from milestone payments and double-digit royalties on sales of Veregen in these countries, as well as certain payments related to the manufacture and supply of the finished product.

Nordic is planning to launch Veregen in the Czech Republic, Slovakia, Poland and Hungary during 2013. MAAs for the other countries are in preparation.

After conclusion of this agreement, marketing partnerships for Veregen now exist for all 17 countries included in the second wave of the European approval procedure, as well as for numerous other markets.

Veregen is already being marketed in the US (Fougera ), Germany, Austria and Switzerland (by Abbott ), and Spain (by Bial-Portela). Marketing authorisations in additional countries are granted or expected within the next few months. Medigene has entered into several marketing partnerships for Veregen across Europe, Asia, and America and is planning to continue this global licensing strategy to further exploit the market potential of the product.



Agreement Information:
Agreement Status: New Date Announced: 29 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Veregen sinecatechins Polyphenon E
Therapeutic Area: General Anti-infectives Systemic
Indication: Genital warts
Techonology/Field: N/A



Agreement Information:
Agreement Status: New Date Announced: 29 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Veregen sinecatechins Polyphenon E
Therapeutic Area: General Anti-infectives Systemic
Indication: Genital warts
Techonology/Field: N/A
×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.